01 / RESEARCH SUMMARY
Retatrutide Research Summary
Retatrutide (LY3437943) is an investigational triple agonist that activates GIP, GLP-1 and glucagon receptors in a single molecule. The incretin activity reduces appetite and improves glucose control, while glucagon receptor activity is thought to raise energy expenditure and liver fat burning. In a 2023 phase 2 trial published in NEJM, the 12 mg arm produced a 24.2% mean weight reduction at 48 weeks, the largest seen with any obesity drug at that point. Phase 3 trials are evaluating it for obesity, diabetes and related conditions.
Read the full guide →02 / WHY RESEARCHERS STUDY IT
Why Retatrutide draws research interest
These are the areas researchers and the peptide community explore Retatrutide for most often. They describe what is being studied — not proven benefits, approved uses, or promised results.
Weight loss
Up to 24% average weight loss at 48 weeks in phase 2.
Blood sugar control
Improved HbA1c and glucose in type 2 diabetes trials.
Liver fat
Produced large reductions in liver fat in phase 2 substudies.
Evidence ranges from early lab work to large clinical trials depending on the use — see the sections below for the data and sources.
03 / DOSING & RECONSTITUTION
Dosing & Reconstitution Guide
A single practical dilution with accurate dosing, step by step
Standard Approach (1 mL = 10 mg/mL)
- Reconstitute: Add 1 mL bacteriostatic water to one 10 mg vial → final concentration 10 mg/mL (10,000 mcg/mL).
- Typical range: 0.5–12 mg 1x daily · 1–2x weekly (split dose), As long as needed.
- Easy measuring: At 10 mg/mL, 1 unit ≈ 100 mcg on a U-100 syringe, so doses read at 5–120 units.
- Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
| Protocol | Dose range | Frequency | Cycle | Time off | Half-life | Fasted | Route |
|---|---|---|---|---|---|---|---|
| Injectable · Subq | 0.5–12 mg | 1x daily · 1–2x weekly (split dose) | As long as needed | As needed | ~6 days | No | Subq |
| Obesity · Phase 2 (2023) | 1 / 4 / 8 / 12 mg | Once weekly | 48 weeks | Subcutaneous (study formulation) |
04 / RECONSTITUTION CALCULATOR
Mix & measure Retatrutide · 10 mg
Pre-filled with this protocol's recommended BAC water and starting dose — edit any field to run your own numbers.
- CONCENTRATION
- 10.00 mg/mL
- DRAW VOLUME
- 0.050 mL
- ON THE SYRINGE
- 5.0 units
- DOSES / VIAL
- 20
Reconstitution math only. U-100 syringe: 100 units = 1 mL.
Reconstitution GuideFull calculator →05 / STORAGE
Storage Instructions
Lyophilized (powder)
Store in the freezer at −20 °C (−4 °F) for long-term storage, or refrigerated at 2–8 °C for shorter periods. Keep dry, sealed and away from light. Let a frozen vial reach room temperature before opening to avoid condensation.
Reconstituted
Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days. Do not freeze. Keep away from heat and direct light, and avoid repeated temperature swings. Swirl gently — never shake.
Reconstitution steps
- Wipe the vial stopper with an alcohol swab.
- Draw the BAC water and release it slowly down the inside wall of the vial.
- Swirl or roll gently until fully dissolved — don't shake.
- Label with the date and concentration and refrigerate.
06 / RESEARCH FINDINGS
What Research Shows
Human research
2023 · Phase 2 · NEJM · 338 participants
24.2% mean weight reduction at 48 weeks
The 12 mg target-dose arm had a mean weight change of −24.2%, versus −2.1% with placebo. Week 24 was the primary endpoint; week 48 was a secondary endpoint. This placebo-controlled trial was not a direct comparison with tirzepatide.
Read the primary study- A phase 2 trial evaluated weight reduction in adults with obesity or overweight and a weight-related condition.
- Combined GIP, GLP-1 and glucagon receptor activation is an investigational metabolic research target.
Research context
Retatrutide is investigational in the cited study, not a prescription-label dosing reference. The community-provided 3G-RT mapping does not verify the vendor product or its suitability for human use.
07 / MOLECULAR BIOLOGY
How Retatrutide Works
Investigational mechanism
GIP, GLP-1 and glucagon receptors
Investigational triple receptor agonism combines incretin signaling with glucagon-receptor activity. Research examines appetite, glucose regulation and energy metabolism.
- 01
Triple receptor agonism
A single investigational molecule activates GLP-1, GIP and glucagon receptors. Combining these activities is the defining difference from a dual incretin agonist.
- 02
GLP-1 and GIP pathways
Incretin signaling contributes to glucose-dependent insulin secretion and appetite regulation. The contribution of each receptor cannot be quantified from the weight-loss result alone.
- 03
Glucagon receptor activity
Glucagon signaling affects hepatic glucose production and energy metabolism. Its contribution is balanced with incretin activity; increased human energy expenditure should not be assumed from receptor activity alone.
- 04
Metabolic outcomes
Clinical studies measure weight and other metabolic outcomes. These results require their own evidence and do not establish that every proposed mechanism occurs to the same extent in people.
Adamantane & the blood–brain barrier
Chemically attaching an adamantane group to a peptide can increase its lipid (fat) solubility. Researchers hypothesize that this modification may help certain compounds cross the tightly regulated blood–brain barrier. The effect depends on the specific modified molecule; greater lipid solubility alone does not establish brain delivery or clinical benefit. This does not apply automatically to the unmodified peptide and is not a reconstitution additive.
08 / LIFESTYLE FACTORS
Lifestyle Factors
- Protein: aim for adequate protein (about 0.7–1 g per lb of goal body weight) to preserve muscle during weight loss.
- Resistance training: lift 2–4x per week to protect lean mass.
- Hydration & fiber: drink plenty of water and eat fiber to reduce constipation and nausea.
- Meal size: eat smaller meals and stop at fullness; greasy, heavy meals worsen GI side effects.
- Titrate slowly: stay at a dose until side effects settle before increasing.
09 / BENEFITS & SIDE EFFECTS
Potential Benefits & Side Effects
Potential Benefits
- Significant reduction in appetite and food noise
- Clinically meaningful weight loss
- Improved blood sugar and insulin sensitivity
- Improvements in blood pressure, lipids and liver fat
Side Effects
- Nausea, vomiting, diarrhea or constipation (most common, usually during dose increases)
- Reduced appetite to the point of under-eating
- Fatigue and occasional headache
- Increased heart rate (especially triple/glucagon agonists)
- Rare: gallbladder problems or pancreatitis — seek care for severe abdominal pain
10 / STUDIES
Studies & references
11 / SAFETY
Safety considerations
- Verify the active identity, lot number, and matching certificate of analysis. Testing does not by itself establish sterility or suitability for human use.
- Follow documented product-specific storage and preparation requirements; stability and diluent compatibility depend on the formulation.
- Research powders are not interchangeable with prescription formulations. Do not infer an injection or nasal protocol from a concentration calculation.
- For medical care, pregnancy, existing conditions, or medication interactions, consult a qualified healthcare professional.
12 / RECOMMENDED SOURCE
Recommended Source
For research peptides, we point researchers to Orbitrex Peptides for Retatrutide.
Why Orbitrex?
- Family-owned & independently tested: Multiple laboratories verify quality, with batch-specific testing in every COA.
- Everyday value: Buy 4, Get 1 Free on eligible products.
- Loyalty credit: 5% back in loyalty credit for future purchases.
- VerifyPass discount: 20% off for qualifying groups — stacks with affiliate codes.
- Free 2nd Day shipping: Free UPS 2nd Day Air on orders $200+, applied automatically at checkout.
All products are for research use only. Availability and offers subject to change.